491 related articles for article (PubMed ID: 18253142)
1. The effect of globalization of drug manufacturing, production, and sourcing and challenges for American drug safety.
Woo J; Wolfgang S; Batista H
Clin Pharmacol Ther; 2008 Mar; 83(3):494-7. PubMed ID: 18253142
[TBL] [Abstract][Full Text] [Related]
2. [An analysis of the pharmaceuticals market in Vietnam].
Simonet D
Sante; 2001; 11(3):155-60. PubMed ID: 11641078
[TBL] [Abstract][Full Text] [Related]
3. Preparing for an FDA preapproval inspection.
Blackmer RA
Qual Assur; 1994 Dec; 3(4):389-403. PubMed ID: 7613749
[TBL] [Abstract][Full Text] [Related]
4. The history and contemporary challenges of the US Food and Drug Administration.
Borchers AT; Hagie F; Keen CL; Gershwin ME
Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
[TBL] [Abstract][Full Text] [Related]
5. Generic Drugs Not as Safe as FDA Wants You to Believe.
White CM
Ann Pharmacother; 2020 Mar; 54(3):283-286. PubMed ID: 31615266
[TBL] [Abstract][Full Text] [Related]
6. Policy implications of drug importation.
Palumbo FB; Mullins CD; Slagle AF; Rizer J
Clin Ther; 2007 Dec; 29(12):2758-67. PubMed ID: 18201594
[TBL] [Abstract][Full Text] [Related]
7. International Conference on Harmonisation; guidance on good manufacturing practice for active pharmaceutical ingredients; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2001 Sep; 66(186):49028-9. PubMed ID: 12358036
[TBL] [Abstract][Full Text] [Related]
8. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
World Health Organ Tech Rep Ser; 1999; 885():i-vi, 1-156. PubMed ID: 10352573
[TBL] [Abstract][Full Text] [Related]
9. Drugs and biologics in pregnancy and breastfeeding: FDA in the 21st century.
Kweder SL
Birth Defects Res A Clin Mol Teratol; 2008 Sep; 82(9):605-9. PubMed ID: 18704917
[No Abstract] [Full Text] [Related]
10. Pharmacological mechanism-based drug safety assessment and prediction.
Abernethy DR; Woodcock J; Lesko LJ
Clin Pharmacol Ther; 2011 Jun; 89(6):793-7. PubMed ID: 21490594
[TBL] [Abstract][Full Text] [Related]
11. ICH: an exclusive club of drug regulatory agencies and drug companies imposing its rules on the rest of the world.
Prescrire Int; 2010 Aug; 19(108):183-6. PubMed ID: 20939460
[TBL] [Abstract][Full Text] [Related]
12. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
World Health Organization
World Health Organ Tech Rep Ser; 2005; 929():1-142, backcover. PubMed ID: 16353684
[TBL] [Abstract][Full Text] [Related]
13. Deterring the importation of counterfeit pharmaceutical products.
Stearn DW
Food Drug Law J; 2004; 59(4):537-61. PubMed ID: 15875351
[No Abstract] [Full Text] [Related]
14. US drug shortages are set to reach record high in 2011, report says.
Tanne JH
BMJ; 2011 Dec; 343():d8307. PubMed ID: 22194406
[No Abstract] [Full Text] [Related]
15. FDA perspective on specifications for biotechnology products--from IND to PLA.
Murano G
Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677
[TBL] [Abstract][Full Text] [Related]
16. Human and veterinary drugs: good manufacturing practices and proposed exemptions for certain OTC products.
Fed Regist; 1978 Sep; 43(190 Pt 2):45013-89. PubMed ID: 10316700
[No Abstract] [Full Text] [Related]
17. ISO 9000. Policy implications for FDA. Taking the pulse of increasing global use of the ISO series of uniform quality standards by FDA regulated industries.
Schwemer WL; Lynch MA
J Parenter Sci Technol; 1993; 47(3):101-18. PubMed ID: 8360802
[No Abstract] [Full Text] [Related]
18. Specifications from a biotechnology industry perspective.
Garnick RL
Dev Biol Stand; 1997; 91():31-6. PubMed ID: 9413680
[TBL] [Abstract][Full Text] [Related]
19. Regulatory and quality considerations for continuous manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
Allison G; Cain YT; Cooney C; Garcia T; Bizjak TG; Holte O; Jagota N; Komas B; Korakianiti E; Kourti D; Madurawe R; Morefield E; Montgomery F; Nasr M; Randolph W; Robert JL; Rudd D; Zezza D
J Pharm Sci; 2015 Mar; 104(3):803-12. PubMed ID: 25830179
[TBL] [Abstract][Full Text] [Related]
20. Challenges associated with the development, manufacturing, and delivery of cellular medicines.
Preti RA
Cancer J; 2001; 7 Suppl 2():S62-6. PubMed ID: 11777266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
